As an executive with over two decades of experience in the biopharma industry, Michelle Calhoun has demonstrated a proven track record of success in leading global sales and marketing teams that have achieved impressive annual revenue targets of $1B+. Her extensive expertise in global CDMO sales, market development, business development, and strategic planning make her a valuable addition to the Scorpius leadership team, helping to build a robust commercial foundation for the organization.
Career highlights include recently serving as Vice President, Commercial Operations for Curia, where she played an integral role leading inside sales, proposals, communications, e-commerce, and marketing with a successful company rebrand. Prior to that, she spent 12 years at AbbVie CDMO as Head of Business Development, Sales & Marketing, and held various roles within Procurement and R&D.
Her academic achievements include a Bachelor of Science degree in Chemistry from Central Michigan University, as well as Project Management and Certified Purchasing Management certifications. She serves as an interim Chief Commercial Officer and as a Senior Advisor on the Executive Leadership Team at Scorpius BioManufacturing.
Steve joined Scorpius as the Vice President of Business Development in 2022; he brings extensive experience in various roles throughout business development. He spent 12 years in the industrial gasses industry with Linde Gas, and then joined W.L. Gore in the Startup Biopharmaceutical division working on a Commercial Business/Market Development role for Bulk Drug Substance Single-Use items. Prior to joining Scorpius, he spent 3 years with Catalent Biologics, focused on Drug Substance Business Development in the US for early-stage clinical programs with clients to bring life-changing therapies to the market.
Steve holds a BS in Chemical Engineering from Pennsylvania State University and an MBA in Marketing from Robert Morris University.
See more insights from Steve Lavezoli in his video Q&A, “Identifying the Right CDMO Partner”, and his article, “3 Key Trends Shaping the CDMO Industry”.
Andrew Handorf joined Scorpius as the Director of Proposals in March of 2023, where he works closely with the technical and commercial teams to generate customized solutions that meet each program’s unique requirements in terms of scope, timeline, and price. Prior to Scorpius, Andrew spent 6 years at Catalent, where he managed the Protein Therapeutics Drug Substance Proposals team and supported the implementation of a variety of strategic initiatives focused on efficiencies in business operations and cross-site integration. Andrew holds a B.S. in Biology and Chemistry from Edgewood College and a Ph.D. in Biomedical Engineering from the University of Wisconsin-Madison.